A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
2021 · Journal of Hematology & Oncology · 211 citations
https://doi.org/10.1186/s13045-021-01170-7
L
Lisha Ai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
64
Papers
2.2K
Citations
26
h-index
41
i10-index
Lisha Ai is an academic researcher from Tongji University. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 26, co-authored 55 publications.
ORCID: 0000-0003-0310-8503Papers by this author
worksMyeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation
2019 · Molecular Cancer · 142 citations
https://doi.org/10.1186/s12943-019-1011-5
Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis
2018 · Cancer Cell International · 54 citations
https://doi.org/10.1186/s12935-017-0498-3
Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival
2021 · The Breast · 17 citations
https://doi.org/10.1016/j.breast.2021.03.006
Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis
2024 · Annals of Medicine · 12 citations
https://doi.org/10.1080/07853890.2024.2338604
Studies Progression on the Function of Autophagy in Viral Infection
2021 · Frontiers in Cell and Developmental Biology · 9 citations
https://doi.org/10.3389/fcell.2021.772965
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat